Reduced complications and mortality after admission for head and neck cancer in patients with previous dental scaling: a retrospective cohort study based on real-world data

既往接受过洗牙治疗的头颈癌患者入院后并发症和死亡率降低:一项基于真实世界数据的回顾性队列研究

阅读:1

Abstract

BACKGROUND: The association between oral health and cancer outcomes remains unclear. The purpose of this study was to evaluate the complications and mortality after admission of head and neck cancer (HNC) in patients with and without dental scaling (DS). METHODS: We used data from public health insurance and identified 121,973 patients with admission of HNC aged ≥ 18 years who received inpatient care in 2006-2020. The outcomes during the admission of HNC were compared between patients who had received DS or not within the previous 24 months before admission. The adjusted odds ratios (HRs) and 95% confidence intervals (CIs) of complications and mortality associated with DS were analyzed in the multivariate Cox proportional regression models. RESULTS: We found that DS was significantly associated with reduced risks of septicemia (OR 0.84, 95% CI 0.81-0.88), stroke (OR 0.87, 95% CI 0.80-0.95), pneumonia (OR 0.88, 95% CI 0.84-0.91), urinary tract infection (OR 0.88, 95% CI 0.80-0.97), and 30-day in-hospital mortality (OR 0.88, 95% CI 0.85-0.92). Compared with HNC patients without DS, HNC patients with DS had a shortened length of hospital stay (p < 0.0001), decreased medical expenditures (p < 0.0001), and reduced risks of intensive care (OR 0.92, 95% CI 0.89-0.95) after admission of HNC. CONCLUSION: In conclusion, we suggested that HNC patients who received DS had reduced complications and mortality compared with those without DS. It is essential to interpret this association with caution due to the confounding factors involved. Our study implied the possibility that clinical physicians may encourage HNC patients to receive regular DS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。